# BGN

## Overview
The BGN gene encodes the protein biglycan, a small leucine-rich proteoglycan that plays a crucial role in the extracellular matrix (ECM) organization and cellular signaling. Biglycan is characterized by its leucine-rich repeat (LRR) domains and is involved in various biological processes, including collagen fibrillogenesis, bone formation, and immune response modulation. It interacts with multiple proteins, such as collagens, growth factors, and toll-like receptors, influencing structural integrity and signaling pathways. Biglycan's involvement in inflammatory processes and its regulatory role in cell signaling underscore its importance in maintaining tissue homeostasis and facilitating cellular communication. Mutations in the BGN gene are linked to genetic disorders like X-linked spondyloepimetaphyseal dysplasia and Meester-Loeys syndrome, while altered expression levels are associated with cancer progression (Mizumoto2017Pathophysiological; Merline2009The; Zhang2022BGN).

## Structure
Biglycan (BGN) is a small leucine-rich repeat proteoglycan (SLRP) with a molecular structure that includes a 38 kD polypeptide core composed of 10 leucine-rich repeats (LRRs). These LRRs are flanked by cysteine-rich domains and contain two glycosaminoglycan (GAG) attachment sites at the amino-terminus (Rafii2006Biglycan). The primary structure of biglycan is highly conserved across species, with mouse and human biglycans being over 95% identical at the amino acid level (Rafii2006Biglycan).

The secondary structure of biglycan includes beta-sheets and alpha-helices, contributing to its characteristic horseshoe shape in the tertiary structure. This shape facilitates protein-protein interactions, such as binding to collagens and TGF-β family members (Rafii2006Biglycan). Biglycan exists in two forms in muscle: a 40 kD N-glycosylated form lacking GAG chains and a 75 kD proteoglycan form (Rafii2006Biglycan).

Post-translational modifications of biglycan include glycosylation, which is crucial for its function in binding to other proteins, such as α-dystroglycan, although not necessary for binding to α- and γ-sarcoglycan (Rafii2006Biglycan). The presence of both glycanated and non-glycanated forms suggests potential distinct functions in muscle (Rafii2006Biglycan).

## Function
Biglycan (BGN) is a small leucine-rich proteoglycan that plays a significant role in the organization and assembly of the extracellular matrix (ECM) in healthy human cells. It binds to collagen types I, II, III, V, and VI, contributing to the structural integrity and organization of connective tissues (Merline2009The; Miguez2019Evidence). BGN is involved in collagen fibrillogenesis, where it coordinates the assembly of collagen fibrils, particularly in tissues like the cornea and tendons (Merline2009The).

BGN also interacts with various growth factors and receptors, influencing cell signaling pathways. It binds to bone morphogenetic proteins (BMPs), such as BMP-2 and BMP-4, enhancing their activity and promoting osteoblast differentiation, which is crucial for bone formation and homeostasis (Miguez2019Evidence; Moreno2005Biglycan). BGN's interaction with the transforming growth factor (TGF)-β family and Wnt signaling pathways further underscores its role in cell signaling and tissue repair (Miguez2019Evidence).

In addition to its structural and signaling roles, BGN is involved in inflammatory processes. It interacts with toll-like receptors TLR4 and TLR2 in macrophages, activating proinflammatory pathways and contributing to immune responses (Schaefer2005The). These diverse functions highlight BGN's importance in maintaining tissue integrity and facilitating cellular communication.

## Clinical Significance
Mutations in the BGN gene, which encodes the proteoglycan biglycan, are associated with several genetic disorders. Two missense mutations, p.Lys147Glu and p.Gly259Val, in BGN cause X-linked spondyloepimetaphyseal dysplasia, a condition characterized by anomalies in the spine and long bones, leading to short stature and osteoarthritic changes. These mutations affect biglycan's stability and its ability to bind with TGFβ (Mizumoto2017Pathophysiological). Additionally, mutations such as p.Trp2* and p.Gln303Pro, or large deletions in BGN, are linked to Meester-Loeys syndrome, which is marked by early-onset thoracic aortic aneurysms and dissections, connective tissue features, and craniofacial dysmorphisms. This condition is associated with increased TGFβ signaling, similar to Loeys-Dietz syndrome (Meester2024Expanding; Mizumoto2017Pathophysiological).

Altered expression of BGN is also implicated in various cancers. In gastric cancer, BGN is significantly overexpressed, and its expression correlates with immune cell infiltration, suggesting a role in the tumor's immune environment (Zhang2022BGN). In bladder cancer, high BGN expression is linked to poor prognosis and is associated with epithelial-mesenchymal transition, a process that facilitates cancer invasion and metastasis (Schulz2019Prognostic).

## Interactions
Biglycan (BGN) is known to interact with several proteins, playing a significant role in various biological processes. BGN interacts with toll-like receptors TLR2 and TLR4, with a stronger affinity for TLR2, leading to the upregulation of osteogenic factors such as BMP-2 and ALP in human aortic valve interstitial cells (Song2012Biglycan). In macrophages, BGN acts as a proinflammatory factor by signaling through TLR4 and TLR2, activating pathways like ERK, p38, and NF-κB, which are crucial for inflammatory responses (Schaefer2005The).

BGN also binds to transforming growth factor β (TGF-β) isoforms, inhibiting their binding to receptors, with decorin and biglycan being more effective inhibitors compared to fibromodulin (Hildebrand1994Interaction). In the context of bone morphogenetic protein (BMP) signaling, BGN binds directly to BMP4 and modulates its activity, enhancing the anti-BMP4 activity of chordin (Moreno2005Biglycan). BGN's interaction with BMP-2 and its type I receptor, ALK6, enhances BMP-2 signaling, suggesting a role in osteogenesis (Miguez2011Role). These interactions highlight BGN's involvement in both inflammatory and developmental processes.


## References


[1. (Miguez2011Role) P.A. Miguez, M. Terajima, H. Nagaoka, Y. Mochida, and M. Yamauchi. Role of glycosaminoglycans of biglycan in bmp-2 signaling. Biochemical and Biophysical Research Communications, 405(2):262–266, February 2011. URL: http://dx.doi.org/10.1016/j.bbrc.2011.01.022, doi:10.1016/j.bbrc.2011.01.022. This article has 43 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2011.01.022)

[2. (Mizumoto2017Pathophysiological) Shuji Mizumoto, Tomoki Kosho, Shuhei Yamada, and Kazuyuki Sugahara. Pathophysiological significance of dermatan sulfate proteoglycans revealed by human genetic disorders. Pharmaceuticals, 10(2):34, March 2017. URL: http://dx.doi.org/10.3390/ph10020034, doi:10.3390/ph10020034. This article has 28 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ph10020034)

[3. (Zhang2022BGN) Shiyu Zhang, Huiying Yang, Xuelian Xiang, Li Liu, Huali Huang, and Guodu Tang. Bgn may be a potential prognostic biomarker and associated with immune cell enrichment of gastric cancer. Frontiers in Genetics, January 2022. URL: http://dx.doi.org/10.3389/fgene.2022.765569, doi:10.3389/fgene.2022.765569. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2022.765569)

[4. (Miguez2019Evidence) Patricia A. Miguez. Evidence of biglycan structure-function in bone homeostasis and aging. Connective Tissue Research, 61(1):19–33, October 2019. URL: http://dx.doi.org/10.1080/03008207.2019.1669577, doi:10.1080/03008207.2019.1669577. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/03008207.2019.1669577)

[5. (Merline2009The) Rosetta Merline, Roland M. Schaefer, and Liliana Schaefer. The matricellular functions of small leucine-rich proteoglycans (slrps). Journal of Cell Communication and Signaling, 3(3–4):323–335, October 2009. URL: http://dx.doi.org/10.1007/s12079-009-0066-2, doi:10.1007/s12079-009-0066-2. This article has 145 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s12079-009-0066-2)

[6. (Meester2024Expanding) Josephina A. N. Meester, Anne Hebert, Maaike Bastiaansen, Laura Rabaut, Jarl Bastianen, Nele Boeckx, Kathryn Ashcroft, Paldeep S. Atwal, Antoine Benichou, Clarisse Billon, Jan D. Blankensteijn, Paul Brennan, Stephanie A. Bucks, Ian M. Campbell, Solène Conrad, Stephanie L. Curtis, Majed Dasouki, Carolyn L. Dent, James Eden, Himanshu Goel, Verity Hartill, Arjan C. Houweling, Bertrand Isidor, Nicola Jackson, Pieter Koopman, Anita Korpioja, Minna Kraatari-Tiri, Liina Kuulavainen, Kelvin Lee, Karen J. Low, Alan C. Lu, Morgan L. McManus, Stephen P. Oakley, James Oliver, Nicole M. Organ, Eline Overwater, Nicole Revencu, Alison H. Trainer, Bhavya Trivedi, Claire L. S. Turner, Rebecca Whittington, Andreas Zankl, Dominica Zentner, Lut Van Laer, Aline Verstraeten, and Bart L. Loeys. Expanding the clinical spectrum of biglycan-related meester-loeys syndrome. npj Genomic Medicine, March 2024. URL: http://dx.doi.org/10.1038/s41525-024-00413-z, doi:10.1038/s41525-024-00413-z. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41525-024-00413-z)

[7. (Song2012Biglycan) Rui Song, Qingchun Zeng, Lihua Ao, Jessica A. Yu, Joseph C. Cleveland, Ke-seng Zhao, David A. Fullerton, and Xianzhong Meng. Biglycan induces the expression of osteogenic factors in human aortic valve interstitial cells via toll-like receptor-2. Arteriosclerosis, Thrombosis, and Vascular Biology, 32(11):2711–2720, November 2012. URL: http://dx.doi.org/10.1161/ATVBAHA.112.300116, doi:10.1161/atvbaha.112.300116. This article has 113 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1161/ATVBAHA.112.300116)

[8. (Hildebrand1994Interaction) A Hildebrand, M Romarís, L M Rasmussen, D Heinegård, D R Twardzik, W A Border, and E Ruoslahti. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor β. Biochemical Journal, 302(2):527–534, September 1994. URL: http://dx.doi.org/10.1042/bj3020527, doi:10.1042/bj3020527. This article has 809 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1042/bj3020527)

[9. (Schulz2019Prognostic) Gerald B. Schulz, Tobias Grimm, Christine Sers, Pamela Riemer, Manal Elmasry, Thomas Kirchner, Christian G. Stief, Alexander Karl, and David Horst. Prognostic value and association with epithelial-mesenchymal transition and molecular subtypes of the proteoglycan biglycan in advanced bladder cancer. Urologic Oncology: Seminars and Original Investigations, 37(8):530.e9-530.e18, August 2019. URL: http://dx.doi.org/10.1016/j.urolonc.2019.05.011, doi:10.1016/j.urolonc.2019.05.011. This article has 23 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.urolonc.2019.05.011)

[10. (Rafii2006Biglycan) Michael S. Rafii, Hiroki Hagiwara, Mary Lynn Mercado, Neung S. Seo, Tianshun Xu, Tracey Dugan, Rick T. Owens, Magnus Hook, David J. McQuillan, Marian F. Young, and Justin R. Fallon. Biglycan binds to α‐ and γ‐sarcoglycan and regulates their expression during development. Journal of Cellular Physiology, 209(2):439–447, August 2006. URL: http://dx.doi.org/10.1002/jcp.20740, doi:10.1002/jcp.20740. This article has 51 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jcp.20740)

[11. (Moreno2005Biglycan) Mauricio Moreno, Rosana Muñoz, Francisco Aroca, Mariana Labarca, Enrique Brandan, and Juan Larraín. Biglycan is a new extracellular component of the chordin–bmp4 signaling pathway. The EMBO Journal, 24(7):1397–1405, March 2005. URL: http://dx.doi.org/10.1038/sj.emboj.7600615, doi:10.1038/sj.emboj.7600615. This article has 89 citations.](https://doi.org/10.1038/sj.emboj.7600615)

[12. (Schaefer2005The) Liliana Schaefer, Andrea Babelova, Eva Kiss, Heinz-J. Hausser, Martina Baliova, Miroslava Krzyzankova, Gunther Marsche, Marian F. Young, Daniel Mihalik, Martin Götte, Ernst Malle, Roland M. Schaefer, and Hermann-Josef Gröne. The matrix component biglycan is proinflammatory and signals through toll-like receptors 4 and 2 in macrophages. Journal of Clinical Investigation, 115(8):2223–2233, August 2005. URL: http://dx.doi.org/10.1172/jci23755, doi:10.1172/jci23755. This article has 671 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci23755)